Publicacións en colaboración con investigadores/as de Complexo Hospitalario Universitario de Santiago (16)

2024

  1. Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of 177Lu-PSMA-617 radioligand-therapy in prostate cancer

    Clinical and Translational Oncology

2022

  1. Circulating Proteins Associated with Response and Resistance to Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

    Cancers, Vol. 14, Núm. 4

2021

  1. Blood-based protein biomarkers in bladder urothelial tumors

    Journal of Proteomics, Vol. 247

  2. Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial

    Molecular Oncology, Vol. 15, Núm. 1, pp. 43-56

  3. Detection of circulating serum protein biomarkers of non-muscle invasive bladder cancer after protein corona-silver nanoparticles analysis by swath-ms

    Nanomaterials, Vol. 11, Núm. 9

2020

  1. A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus

    Clinical and Translational Oncology, Vol. 22, Núm. 9, pp. 1565-1579

  2. Identification of a profile of neutrophil-derived granule proteins in the surface of gold nanoparticles after their interaction with human breast cancer sera

    Nanomaterials, Vol. 10, Núm. 6, pp. 1-18

  3. Potential clinical applications of the personalized, disease-specific protein corona on nanoparticles

    Clinica Chimica Acta, Vol. 501, pp. 102-111

  4. Proteomic investigation on bio-corona of Au, Ag and Fe nanoparticles for the discovery of triple negative breast cancer serum protein biomarkers

    Journal of Proteomics, Vol. 212

2018

  1. Abordaje del paciente con cáncer renal: ¿existe la colaboración entre urología y oncología?

    Actas Urologicas Espanolas

  2. Concurrent chemoradiation for locally advanced stage III non-small cell lung cancer with cisplatin, vinorelbine, and thoracic radiotherapy: a phase II study from the Galician Lung Cancer Group

    Clinical and Translational Oncology, Vol. 20, Núm. 11, pp. 1467-1473

2016

  1. Fluorescence in situ hybridization analysis of the ALK gene in 2,045 non-small cell lung cancer patients from North-Western Spain (Galicia)

    Oncology Letters, Vol. 12, Núm. 2, pp. 1403-1407

  2. Validation of the international metastatic renal-cell carcinoma database consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: The Spanish oncologic genitourinary group (SOGUG) SPAZO study

    Annals of Oncology, Vol. 27, Núm. 4, pp. 706-711

2013

  1. Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor

    Clinical and Translational Oncology, Vol. 15, Núm. 6, pp. 425-433

  2. Erratum: Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor (Clinical and Translational Oncology DOI: 10.1007/s12094-012-0985-x)

    Clinical and Translational Oncology

2011

  1. Expression of notch1 to -4 and their ligands in renal cell carcinoma: A tissue microarray study

    Cancer Genomics and Proteomics, Vol. 8, Núm. 2, pp. 93-101